Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 36NSCLC 9Adenocarcinoma of Lung 5Meningeal Carcinomatosis 4Lung Neoplasms 4Brain Neoplasms 3Respiratory Tract Neoplasms 1Pleural Effusion, Malignant 1Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1Multiple Primary Lung Cancers 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1EGF-R Positive Non-Small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1Adenocarcinoma 1

Interventions

Docetaxel 4pembrolizumab 3Pemetrexed 3Nivolumab 2Cisplatin 2Carboplatin 2tislelizumab 1rofecoxib 1paclitaxel poliglumex 1osimertinib 1nazartinib 1lenvatinib 1cemiplimab 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Radiosurgery 1RO5126766 1Platinum Compounds 1Midazolam 1Gemcitabine 1Gefitinib 1Food 1Esomeprazole 1Drug Therapy 1Dabigatran 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × aflutinib × Thoracic × Clear all
NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡